Cefpodoxime: Difference between revisions
(Remove disease-specific entries now covered by AntibioticDose (4 sections))
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
==General==
==General==
*Type: 3rd generation [[cephalosporin]]
*Type: [[Is Generation::3rd generation]] [[Is DrugClass::cephalosporin]]
*Dosage Forms: tablet, oral suspension
*Dosage Forms: tablet, oral suspension
*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL
*Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL
*Routes of Administration: PO
*Routes of Administration: PO
*Common Trade Names: Cefopodoxine Proxetil, Vantin
*Common Trade Names: Vantin, Cefopodoxine Proxetil


==Adult Dosing==
==Adult Dosing==
===[[Bronchitis]] (chronic)===
===Indications by Disease===
*200mg q 12 h  for 10 days
{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Adult]]
===Acute bacterial infection===
|?Treats disease=Disease
*200mg q 12 h  for 10 days
|?Has Dose=Dose
===[[Pharyngitis]]/Tonsillitis===
|?Has Context=Context
*100mg q 12 h for 5-10 days
|format=table
===Acute community acquired [[pneumonia]]===
|limit=50
*200mg q 12 h for 14 days
|mainlabel=-
===Acute rhino [[sinusitis]]===
|headers=show
*200mg q 12 h for 10 days
|sort=Treats disease
===Skin and soft tissue infection===
}}
*400mg q 12 h for 14 days
===[[Urinary tract infection]], uncomplicated===
*100mg q 12 h for 7 days
===[[Pyelonephritis]]===
*200mg q12 for 10 days


==Pediatric Dosing==
==Pediatric Dosing==
Line 41: Line 36:
*Skin soft tissue infection and uncomplicated [[urinary tract infection]]
*Skin soft tissue infection and uncomplicated [[urinary tract infection]]
**Children >12 years to adolescent: adult dosing
**Children >12 years to adolescent: adult dosing
===Indications by Disease===
{{#ask: [[Has DrugName::Cefpodoxime]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Special Populations==
==Special Populations==
Line 56: Line 64:
*Allergy to class/drug
*Allergy to class/drug
*Caution:
*Caution:
**Hypersensitivity to [[penicillin]
**Hypersensitivity to [[penicillin]]
**Renal impairment
**Renal impairment
**Concurrent nephrotoxic agent
**Concurrent nephrotoxic agent

Latest revision as of 11:08, 20 March 2026

General

  • Type: 3rd generation cephalosporin
  • Dosage Forms: tablet, oral suspension
  • Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Vantin, Cefopodoxine Proxetil

Adult Dosing

Indications by Disease

DiseaseDoseContext
Acute cystitis200 mg BID x10-14dOutpatient, Women Complicated
Acute cystitis200 mg BID x10-14dMen
COPD exacerbation200mg q 12 h for 10 daysBronchitis (chronic)
Periorbital cellulitis400mg BIDOutpatient
Pharyngitis100mg q 12 h for 5-10 daysPharyngitis/Tonsillitis
Pneumonia (main)200 mg BIDOutpatient, Unhealthy
Pyelonephritis200mg PO BID x 10 daysOutpatient
Skin and soft tissue infections400mg q 12 h for 14 daysSkin and soft tissue infection

Pediatric Dosing

General

  • Infant ≥2 months to children <12 years: 10mg/kg/day (maximum 200mg/dose) q 12 h
  • Children >12 years to adolescent: 100 to 400mg q 12 h

Specific indication

  • Bronchitis (chronic), acute bacterial infection
    • Adult dosing for Infant ≥2 months to children <12 years
  • Acute otitis media
    • Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 5 days, duration according to AAP recommendation [1]: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-**5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
  • Pharyngitis/tonsillitis:
    • Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100mg/dose) q 12 h for 5-10 days
    • Children >12 years to adolescent: adult dosing
  • Acute sinusitis
    • Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) [2]
    • Children >12 years to adolescent: adult dosing
  • Skin soft tissue infection and uncomplicated urinary tract infection
    • Children >12 years to adolescent: adult dosing


Indications by Disease

DiseaseDoseContext
Acute cystitis10mg/kg/day PO divided BID (max 200mg/dose)Pediatric
Acute otitis media10mg/kg PO daily x7-10 daysPrior Month Treatment
Periorbital cellulitis10 mg/kg per day divided every 12 hours, max 200 mgOutpatient
Pyelonephritis10mg/kg/day PO divided BID x 10 days (max 200mg/dose)Pediatric Outpatient
Sinusitis5mg/kg/dose (max 200mg/dose) q12h x 10 daysAcute sinusitis

Special Populations

  • Pregnancy Rating: B
  • Lactation: excreted in breast milk, not recommended for nursing women
  • Renal Dosing
    • Adult
      • CrCl >30 mL/minute: dosage adjustment not needed
      • CrCl <30 mL/minute: administer q 24 h
      • Hemodialysis: 3 times/week following dialysis
    • Pediatric: not defined
  • Hepatic Dosing: dosage adjustment not nescessary

Contraindications

  • Allergy to class/drug
  • Caution:
    • Hypersensitivity to penicillin
    • Renal impairment
    • Concurrent nephrotoxic agent
    • Seizure disorder
    • Recent antibiotic-associated colitis

Adverse Reactions

Serious (<1%)

Common

Pharmacology

  • Half-life: 2-3 h, prolonged to ~10 h if CrCl <30 mL/minute
  • Metabolism: De-esterified in GI tract to active metabolite
  • Excretion: Urine
  • Mechanism of Action: Inhibit bacterial cell walls synthesis (binding to penicillin-binding proteins (PBPs)

See Also

References

  1. ↑ Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999
  2. ↑ Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112
Retrieved from "https://www.wikem.org/w/index.php?title=Cefpodoxime&oldid=386739"